Medicine and HealthFrontiers in Immunology
IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models
H. Shi, A. Li, et al.
Discover how IL-15-armored claudin 18.2-targeting CAR-T cells are revolutionizing antitumor therapy in pancreatic and melanoma models. This groundbreaking study led by Hongtai Shi, Andi Li, Zhenyu Dai, and others showcases enhanced in vitro expansion and surprising tumor angiogenesis, indicating a promising direction for solid tumor treatments.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Locoregional delivery of IL-13Rx2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
C. E. Brown, J. C. Hibbard, et al.
Medicine and Health
Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy
Y. Li, Y. Cong, et al.
Biology
Transplanted human iPSC-derived vascular endothelial cells promote functional recovery by recruitment of regulatory T cells to ischemic white matter in the brain
B. Xu, H. Shimauchi-ohtaki, et al.
Medicine and Health
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
D. Nixdorf, M. Sponheimer, et al.
